FDA has approved the first ketamine-based antidepressant

Taken as a nasal spray, Spravato may quickly help people with hard-to-treat depression

ketamine laboratory

KETAMINE’S SECOND LIFE  A laboratory is churning out a newly approved antidepressant nasal spray that is based on ketamine, giving that powerful, old anesthetic new life as a treatment for severe depression.

Janssen Pharmaceuticals, Inc. 

This article is only available to Science News subscribers.

Subscribers, enter your e-mail address to access our archives.

Not a subscriber?

Science News is a nonprofit.

Support us by subscribing now.

More Stories from Science News on Health & Medicine

From the Nature Index

Paid Content